Authors: LARSEN TB LASSEN JF DAHLERERIKSEN BS PETERSEN PH BRANDSLUND I

Citation: Tb. Larsen et al., EFFECT OF ANTICOAGULANT-THERAPY ON THE HYPERCOAGULABLE STATE IN PATIENTS CARRYING THE FACTOR-V ARG506GLN MUTATION, Thrombosis research, 92(4), 1998, pp. 157-162

Authors: BRANDSLUND I DAHLERERIKSEN BS LASSEN JF DAHLERERIKSEN K LARSEN TB

Citation: I. Brandslund et al., CHANGE FROM PHENPROCOUMON TO WARFARIN - SCHEME AND PROGRAM FOR MONITORING AND DOSE-ADJUSTMENTS, Thrombosis and haemostasis, 1997, pp. 2865-2865

Authors: LASSEN JF DAHLERERIKSEN BS DAHLERERIKSEN K LARSEN TB HUSTED SE BRANDSLUND I

Citation: Jf. Lassen et al., EFFECT OF CHANGE FROM PHENPROCOUMON TO WARFARIN ON MARKERS OF COAGULATION AND FIBRINOLYSIS, Thrombosis and haemostasis, 1997, pp. 2885-2885

Authors: DAHLERERIKSEN BS LASSEN JF LUND ED LAURITZEN T BRANDSLUND I

Citation: Bs. Dahlereriksen et al., C-REACTIVE PROTEIN IN GENERAL-PRACTICE - HOW COMMONLY IS IT USED AND WHY, Scandinavian journal of primary health care, 15(1), 1997, pp. 35-38

Authors: DAHLERERIKSEN BS LASSEN JF PETERSEN PH LUND ED LAURITZEN T BRANDSLUND I

Citation: Bs. Dahlereriksen et al., EVALUATION OF A NEAR-PATIENT TEST FOR C-REACTIVE PROTEIN USED IN DAILY ROUTINE IN PRIMARY HEALTH-CARE BY USE OF DIFFERENCE PLOTS, Clinical chemistry, 43(11), 1997, pp. 2064-2075